New data provided by EpiCept proves that Ceplene, when administered in conjunction with low-dose interleukin-2 (IL-2), provides durable protection from leukaemia relapse in patients with acute myeloid leukaemia.
The data will be presented on 6 June 2009 at the European Hematology Association’s (EHA) 14th Congress in Berlin, Germany.
Follow-up data from patients enrolled in the Phase III trial of Ceplene showed that the group continued to show statistically significant differences in LFS in the overall treatment population (p=0.011) and among the CR1 group (p=0.015).
President and CEO of EpiCept Jack Talley said that Ceplene can provide AML patients with positive and prolonged clinical benefits in preventing relapse of this deadly disease.
“These findings also represent the latest in a number of significant milestones for Ceplene, as we just announced that the drug is now available to patients in major markets throughout the world through our named patient programme agreement with IDIS,” he said.